Illustration of the GAD-7 scale for measuring generalized anxiety.

The GAD-7 in Research: Applications Across Populations

The GAD-7 is a brief self-report scale used to screen for generalized anxiety disorder (GAD) and evaluate the severity of its symptoms. For the full item structure and how to deploy it in Labvanced, see the GAD-7 instrument page. For the scoring procedure and severity bands, see the GAD-7 Scoring and Interpretation guide. This page looks at how the scale has actually been used across different research populations.

Preview of the GAD-7 scale online.

The GAD-7 questionnaire, as shown above, can be imported to your Labvanced account and then edited by clicking on the 'Import' button here.


Join Labavnced today and add the GAD-7 scale to your next online experiment.

Applications Across Research Populations

Since its development, researchers have adapted and tested the GAD-7 across many groups and settings beyond the primary care population it was originally validated in. Here are some examples of how the scale has been used across different fields and populations:

  • General Population: In a general population sample of over 5,000 participants in Germany, the GAD-7 showed strong reliability and construct validity, with a unidimensional structure consistent across age and gender groups. Scores in this general population sample were generally lower than in clinical settings, supporting its effectiveness as a screening tool in non-clinical populations too (Löwe et al., 2008).

  • Sports psychology: In a national sample of over 7,500 collegiate student-athletes in the United States, the GAD-7 (and its 2-item short form, the GAD-2) showed good reliability and construct validity. Higher scores were associated with greater functional and academic difficulties and poorer perceived mental health, supporting the scale's use for anxiety screening in student-athlete populations (Tran, 2020).

  • Pregnant Women: Zhong et al. (2015) evaluated the GAD-7 as a screening tool among 2,978 women attending their first perinatal care visit in Peru. The scale showed good reliability (α = .89) and a one-factor structure, with higher scores associated with poorer self-rated physical and mental health, supporting its diagnostic validity for detecting GAD in pregnant women.

  • Autism: Researchers have explored the GAD-7's reliability for identifying anxiety in individuals with autism spectrum disorder (ASD). Whether the scale is reliable and valid across all autistic populations, including those with intellectual disabilities, remains an open question, but this is an active area of interest for clinical psychologists given that autistic individuals may experience and express anxiety differently (El Baou et al., 2023).

  • Individuals with epilepsy: Among 213 Chinese people with epilepsy, the GAD-7 was used as a screening tool for generalized anxiety disorder. The findings suggested the scale can facilitate earlier detection and appropriate intervention for anxiety in individuals with epilepsy (Tong et al., 2016).

  • Individuals with addiction: In a community drugs treatment service, the GAD-7 was evaluated against the Clinical Interview Schedule-Revised (CIS-R) in 103 patients. The findings supported the GAD-7 as an effective brief screening measure for identifying anxiety disorders in individuals undergoing addiction treatment (Delgadillo et al., 2012).

  • Migraine patients: Among 146 patients seeking treatment for migraine, the GAD-7 was evaluated as a rapid screening tool for anxiety. The study concluded that the scale is a useful instrument for efficiently identifying anxiety in migraine patients, facilitating timely recognition and management (Seo & Park, 2015).

Conclusion

The GAD-7 continues to be validated and used across a wide range of populations well beyond the primary care setting it was originally developed for, from student-athletes to pregnant women to clinical treatment populations. See the GAD-7 instrument page for the scale's full item structure and how to deploy it in Labvanced.


Join Labavnced today and administer the GAD-7 scale online.

References

  • Delgadillo, J., Payne, S., Gilbody, S., Godfrey, C., Gore, S., Jessop, D., & Dale, V. (2012). Brief case finding tools for anxiety disorders: Validation of GAD-7 and GAD-2 in addictions treatment. Drug and Alcohol Dependence, 125(1–2), 37–42. https://doi.org/10.1016/j.drugalcdep.2012.03.011

  • El Baou, C., Bell, G., Saunders, R., Buckman, J. E., Mandy, W., Dagnan, D., ... & Stott, J. (2023). Effectiveness of primary care psychological therapy services for treating depression and anxiety in autistic adults in England: a retrospective, matched, observational cohort study of national health-care records. The Lancet Psychiatry, 10(12), 944-954.

  • Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y. (2008). Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Medical Care, 46(3), 266–274. https://doi.org/10.1097/mlr.0b013e318160d093

  • Seo, J.-G., & Park, S.-P. (2015). Validation of the generalized anxiety disorder-7 (GAD-7) and GAD-2 in patients with migraine. The Journal of Headache and Pain, 16(1). https://doi.org/10.1186/s10194-015-0583-8

  • Tong, X., An, D., McGonigal, A., Park, S.-P., & Zhou, D. (2016). Validation of the generalized anxiety disorder-7 (GAD-7) among Chinese people with epilepsy. Epilepsy Research, 120, 31–36. https://doi.org/10.1016/j.eplepsyres.2015.11.019

  • Tran, A. G. T. T. (2020). Using the GAD-7 and GAD-2 generalized anxiety disorder screeners with student-athletes: Empirical and clinical perspectives. The Sport Psychologist, 34(4), 300–309. https://doi.org/10.1123/tsp.2020-0028

  • Zhong, Q.-Y., Gelaye, B., Zaslavsky, A. M., Fann, J. R., Rondon, M. B., Sánchez, S. E., & Williams, M. A. (2015). Diagnostic validity of the Generalized Anxiety Disorder - 7 (GAD-7) among pregnant women. PLOS ONE, 10(4). https://doi.org/10.1371/journal.pone.0125096